ArticleACS applied materials & interfaces2026
Hemocompatibility of Carbosilane Dendrimers as a Therapeutic siRNA Delivery System across Blood-Brain Barrier.
Article in ACS applied materials & interfaces, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tiered Evaluation of Carbosilane Dendrimer-siRNA Nanoplatform from Single-Cell Biocompatibility to Blood-Brain Barrier Model Dynamics and Murine Alzheimer Model Behavior Assessment.ACS applied materials & interfaces · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of nanocarriers offers a promising strategy for the delivery of therapeutics to the central nervous system. However, the clinical translation of nanosystems hinges on their interactions with blood components, which not only dictate their biodistribution and therapeutic efficacy but also may pose potential risks to hemostasis. In this study, we assess the hemocompatibility of a novel, third-generation PEGylated carbosilane dendrimer (G3Si PEG6000) and its dendriplex designed for siRNA delivery across the blood-brain barrier pertinent to Alzheimer's disease. Utilizing a comprehensive array of advanced analytical techniques, we assess cellular responses, cytokine expression, hemorheological properties, hematological parameters, and coagulation dynamics within a physiologically relevant environment. Our findings demonstrate that the investigated nanosystem elicits changes in blood rheology, immune recognition, and the intrinsic coagulation cascade, yet these effects remain below thresholds associated with clinically significant adverse outcomes. Hemolysis was ∼8-fold lower for dendriplexes than the dendrimer in PBS at the highest concentration (accordingly 3.5 ± 0.14% vs 27.46 ± 4.66%, 24 h), in 55% plasma, both formulations were nonhemolytic across all concentrations. Whole blood viscosity increased by up to ∼11% (dendrimer) and ∼16% (dendriplex) relative to the control. At 10 μM, the dendrimer approximately doubled the aPTT, whereas the corresponding dendriplex increased the aPTT by ∼30% of the control. Importantly, neither adverse effects on red blood cell and platelet indices nor toxicological responses in white blood cells were observed under the tested conditions. These findings not only support the translational potential of the studied nanosystem for therapy but also emphasize the critical role of the therapeutic cargo and the formation of a biomolecular corona in shaping the nanocarrier's biological identity and its subsequent interactions within the bloodstream. The results provide a compelling scientific basis for advancing this platform in further investigations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.